N M Davies

Summary

Affiliation: University of Calgary
Country: Canada

Publications

  1. ncbi Clinical pharmacokinetics of naproxen
    N M Davies
    Faculty of Medicine, Department of Pharmacology and Therapeutics, University of Calgary, Alberta, Canada
    Clin Pharmacokinet 32:268-93. 1997
  2. ncbi Clinical pharmacokinetics of tiaprofenic acid and its enantiomers
    N M Davies
    Faculty of Medicine, Department of Pharmacology and Therapeutics, University of Calgary, Canada
    Clin Pharmacokinet 31:331-47. 1996
  3. ncbi Clinical pharmacokinetics of sulindac. A dynamic old drug
    N M Davies
    Faculty of Medicine, Department of Pharmacology and Therapeutics, University of Calgary, Alberta, Canada
    Clin Pharmacokinet 32:437-59. 1997
  4. ncbi Clinical pharmacokinetics of diclofenac. Therapeutic insights and pitfalls
    N M Davies
    Faculty of Medicine, Department of Pharmacology and Therapeutics, University of Calgary, Alberta, Canada
    Clin Pharmacokinet 33:184-213. 1997
  5. ncbi Clinical pharmacokinetics of nabumetone. The dawn of selective cyclo-oxygenase-2 inhibition?
    N M Davies
    Faculty of Medicine, Department of Pharmacology and Therapeutics, University of Calgary, Alberta, Canada
    Clin Pharmacokinet 33:404-16. 1997

Detail Information

Publications5

  1. ncbi Clinical pharmacokinetics of naproxen
    N M Davies
    Faculty of Medicine, Department of Pharmacology and Therapeutics, University of Calgary, Alberta, Canada
    Clin Pharmacokinet 32:268-93. 1997
    ..Although naproxen is excreted into breast milk the amount of drug transferred comprises only a small fraction of the maternal exposure. Significant drug interactions have been demonstrated for probenecid, lithium and methotrexate...
  2. ncbi Clinical pharmacokinetics of tiaprofenic acid and its enantiomers
    N M Davies
    Faculty of Medicine, Department of Pharmacology and Therapeutics, University of Calgary, Canada
    Clin Pharmacokinet 31:331-47. 1996
    ..Relationships between tiaprofenic acid concentrations in biological matrices and therapeutic or toxic effects have not yet been elucidated for this drug...
  3. ncbi Clinical pharmacokinetics of sulindac. A dynamic old drug
    N M Davies
    Faculty of Medicine, Department of Pharmacology and Therapeutics, University of Calgary, Alberta, Canada
    Clin Pharmacokinet 32:437-59. 1997
    ..Significant drug interactions have been demonstrated for dimethylsulphoxide, cyclosporin, furosemide (frusemide), hydrochlorothiazide, methotrexate and cholestyramine...
  4. ncbi Clinical pharmacokinetics of diclofenac. Therapeutic insights and pitfalls
    N M Davies
    Faculty of Medicine, Department of Pharmacology and Therapeutics, University of Calgary, Alberta, Canada
    Clin Pharmacokinet 33:184-213. 1997
    ..Significant drug interactions have been demonstrated for aspirin (acetylsalicylic acid), lithium, digoxin, methotrexate, cyclosporin, cholestyramine and colestipol...
  5. ncbi Clinical pharmacokinetics of nabumetone. The dawn of selective cyclo-oxygenase-2 inhibition?
    N M Davies
    Faculty of Medicine, Department of Pharmacology and Therapeutics, University of Calgary, Alberta, Canada
    Clin Pharmacokinet 33:404-16. 1997
    ..Dosage adjustment may be required in the elderly, patients with active rheumatic disease and those with hepatic impairment, but not in patients with mild-to-moderate renal failure...